Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Rectal Cancer

Interventions

DRUG

Trifluridine/Tipiracil

TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.

RADIATION

intensity-modulated radiotherapy

Trial Locations (1)

RECRUITING

Cancer Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER